1. Abubakr Y, Eng C, Pautret V, Maurel J, Scheithauer W, Kroening H et al. (2006). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol. ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): 3556.
2. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L . (1999). Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884–2890.
3. Arteaga CL . (2001). The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32–40.
4. Badarinath SME, Jennis A . (2004). Cetuximab plus FOLFOX for colorectal (EXPLORE): preliminary safety analysis of a randomized phase III trial. Presented at the 2004 American Society of Clinical Oncology Annual Meeting New Orleans, Louisiana.
5. Barber TD, Vogelstein B, Kingzler KW, Velculescu VE . (2004). Somatic mutations of EGFR in colorectal cancer and glioblastomas. New Engl J Med 351: 2883.